throbber
(cid:38)(cid:68)(cid:83)(cid:86)(cid:88)(cid:74)(cid:72)(cid:79)(cid:3)(cid:40)(cid:91)(cid:75)(cid:76)(cid:69)(cid:76)(cid:87)(cid:3)(cid:20)(cid:19)(cid:19)(cid:21)
`
`Page 1 of 28
`
`

`

`5,501,857
`Page 2
`
`US. PATENT DOCUMENTS
`
`4,129,578
`4,138,498
`4,159,322
`4,405,609
`
`1211978 Celmeretal.
`. 260845.? R
`
`2.!1979 Das ...........
`426m?
`
`424MB}
`611979 Cloyd
`9.31983 Potter
`424! 1??
`
`4,695,466
`4.761.426
`5,104,662
`5,244,669
`5,244,681
`
`9f198? Morishita at a].
`8.11988 Marlin el al.
`#1992 Kalsta et a1.
`911993 Saluh etal.
`911993 Vlnci el al.
`
`424f456
`51411460
`4241451
`4244438
`42672
`
`Page 2 of 28
`
`Page 2 of 28
`
`

`

`US. Patent
`
`Mar. 26, 1996
`
`Sheet 1 of 7
`
`5,501,857
`
`FIGURE 1
`
`Page 3 of 28
`
`Page 3 of 28
`
`
`

`

`US. Patent
`
`Mar. 26, 1996
`
`Sheet 2 of 7
`
`5,501,857
`
`FIGURE2d
`
`48
`
`
`50
`FIGURE2a FIGURE2c
`
`FIGURE2b
`
`w
`
`Wx
`
`Page 4 of 28
`
`Page 4 of 28
`
`

`

`US. Patent
`
`Mar. 26, 1996
`
`Sheet 3 of 7
`
`5,501,857
`
`FIGURE2f
`
`51
`
`FIGUREZe
`
`Page 5 of 28
`
`Page 5 of 28
`
`

`

`US. Patent
`
`Mar. 26, 1996
`
`Sheet 4 of 7
`
`5,501,857
`
`1.00E+10
`
`1.00E+09
`
`1.00E+08
`
`1.00E+07
`
`1.00E+06
`
`1.00E+05
`
`1.00E+04
`
`1.00E+03
`
`1.00E+02
`
`
`
`
`
`CPU/Bolus(logarithmicscale)
`
`VIABLE BACTERIAL COUNTS PER BOLUB
`
`
`
`EEHiEEEiEEEEEKEEEZEiEESEKfi
`
`1:?a:
`
`
`
`
`
`1.00E+01
`
`
`1.00E+00
`
`Page 6 of 28
`
`Bolus #
`
`I MRS
`
`El MRSO
`
`FIGURE 3
`
`Page 6 of 28
`
`

`

`US. Patent
`
`Mar. 26, 1996
`
`Sheet 5 of 7
`
`5,501,857
`
`26'
`
`28'
`
`22'
`
`33'
`
`35'
`
`24'
`
`20'
`
`
`
`38'
`
`42' 44'
`
`32'
`
`34'
`
`37' 36' 30'
`
`40'
`
`FIGURE 4
`
`Page 7 of 28
`
`Page 7 of 28
`
`

`

`US. Patent
`
`Mar. 26, 1996
`
`Sheet 6 of 7
`
`5,501,857
`
`FIGURE5b
`
`FIGURE5d
`
`48
`
`
`FIGURE5a FIGURE5C O
`
`.w
`
`m$
`
`tn
`
`Page 8 of 28
`
`Page 8 of 28
`
`

`

`US. Patent
`
`Mar. 26, 1996
`
`Sheet 7 of 7
`
`5,501,857
`
`F1.0
`
`
`FIGURE5e
`
`
`E ___I§\£“\RP
`bfidv‘fixmflw
`Qan‘w
`
`Page 9 of 28
`
`“-l
`
`mD(
`
`DHI
`
`n
`
`m [
`
`21
`
`Page 9 of 28
`
`

`

`1
`ORAL NUTRITIONAL AND DIETARY
`COMPOSITION
`
`5,501,857
`
`2
`
`This application is a continuation-in-part of U.S. patent
`application Ser. No. 07(920,104 filed Jul. 24, 1992, now US.
`Pat. No. 5,310,555.
`
`TECHNICAL FIELD
`
`This invention relates generally to veterinary nutritional
`and dietary compositions for livestock, and specifically to
`compositions which combine incompatible substances such
`as nutrient supplements and viable direct-fed microbials.
`The invention also relates to a method of preparing a
`shelf-stable
`composition of
`incompatible agents. The
`present invention is particularly well suited to deliver in
`vivo, nearly simultaneously, incompatible supplements such
`as vitamins and minerals and microorganism to cattle,
`sheep, goats, ostriches, and coins in the form of a capsule-
`in-a—capsule.
`
`BACKGROUND OF THE INVENTION
`
`In the past, the development of effective treatments for
`feeding disorders in cattle, sheep and goats has been spurred
`by a desire to maximize yields of meat and dairy products.
`Existing drug-based treatments (see, e.g., US. Pat. No.
`4.?61,426 issued to Martin, et al., and U.S. Pat. No. 4,6105,
`609 issued to Potter), however, have the serious drawback of
`rendering products from treated animals unsalahle for long
`periods under laws designed to protect consumers from
`harmful drug residues. Farmers, unhappy with the need to
`choose between low yields or unsalable products, have long
`sought the development of alternative, drug-free dietary
`treatments. As farmers expand into other livestock markets,
`such as the raising of ostriches and cmus for yields of meat
`and eggs, similar problems occur. The goals of drug-free
`dietary treatments are generally, improved growth and per—
`forrnanee, and especially, appetite stimulation and reestab-
`lishment of the rumen or gastrointestinal microbial popula-
`tions necessary for proper digestion.
`Much attention has been given in recent years to the use
`of certain microorganisms as dietary adjuncts in efi‘orts to
`improve the growth and performance of livestock in general.
`and rcestablishment of rumen or gastrointestinal microbial
`populations in ruminant animals. Such dietary cultures are
`known as probiotics or direct-fed microbials. (Gilliland, S.
`13., 8th lnr’l. Biatech. Syn. Proc, Vol. 2, pp. 923—933
`(1988)). Generally, the microorganisms of such probiotics
`are those that are expected to grow andlor function in the
`intestinal tract or in the rumen of the particular animal and
`can exert certain metabolic actions that influence that ani-
`mal. Various gastrointestinal tract microorganisms which
`have been considered for this type of usage include lacto-
`bacillus oct'dophilus, [acrobacillus plantanon, [actobecil-
`t'us femrenrnm, Lactobocillur caret, Lactobacillns lactis,
`Pediococcos cerevisioe and Streptococcus fizecr'um. These
`bacteria perform one or more of the following functions:
`They compete for villi attachment sites with pathogenic
`microorganisms, control Ph{acidi1y) within the gastrointes-
`tinal tract, produce enzymes and other metabolites which
`benefit digestion, and produce substances capable of inhib—
`iting die growth of other harmful microorganisms. Addi-
`tional microorganisms that could be used for this purpose
`include the live cell yeast, Saccharomyces cerevirioe, the
`fungus, Aspergillus otyzae, and bacteria, Bhidobacrerium
`longum and Pmpionibacten'wn fieudenreichii or the taxo-
`
`10
`
`15
`
`2t}
`
`25
`
`30
`
`35
`
`4o
`
`45
`
`50
`
`55
`
`65
`
`Page 10 of 28
`
`admin equivalents thereof. Live cell yeast cultures and
`fiingi, such as Sacchammyces cerevisiae and Aspergt'llos
`oryzae, have been shown to produce beneficial enzymes and
`raise the pH in the rumen by enhancing the growth of
`bacteria that either utilize lactic acid or ferment fecdstuffs to
`absorbable fatty acids. Bifidobacteria species have been
`shown to be a major colonizer of the undeveloped rumen of
`newborn cattle and the lower intestine of all newborn
`animals. Brfidobacten‘wn longwn may also aid in intestinal!
`rumen pH control and enzyme production. Certain strains of
`Propionibacreriomfi-eudenreichii utilize nm'ien nitrates as a
`food substrate and are,
`therefore, beneficial
`in reducing
`nitrate toxicity in animals exposed to excessive amounts of
`that chemical. This might occur where the cattle are exposed
`to excess nitrates in feeds, to fresh pastures grown during
`drought conditions and to nitrates in water.
`As known in the art, the Food and Drug Administration,
`Center for Veterinary Medicine has published a list of
`microorganisms which they have reviewed and have found
`to present no safety concerns when used in direct-fed
`microbial products in the Official Publication of the Asso-
`ciation of American Food Control Dfiicials, Inc. (AAFCO)
`(1993} at pp. 148—149. the disclosure of which is hereby
`incorporated by reference. Many commercial direct~fed
`microbials are especially important in their non-spore forms,
`i.e. vegetative forms. These vegetative forms may be in the
`dormant state. These microbials are approved for animal
`feeding and an: available to the public from several suppli~
`ers
`
`Common feed additives (AAFCO p. 248—253, 21 CFR
`§573 and 21 CFR §534) are known in the art as carriers for
`animal or livestock feeding purposes. Those which have
`been found to be safe when used in feed, are on the FDA’s
`Generally Recognized as Safe (GRAS) lists. 21 CFR 584.
`The ingredient additives not defined by AAFCO appear on
`the “Least Common Federal Ingredients” list, (AAFCO p.
`248-253).
`'Ib derive maximum benefit from use of probiotics, the
`microorganisms must survive and grow in the rumen andl'or
`intestine. It is thus imperative that the probiotic contain
`viable and active microorganisms at the time of consump-
`tion. The microorganisms used as probiotics, therefore, must
`be stable during preparation and during storage prior to
`consumption.
`The simplest approach to delivery of probiotics is to add
`cultures to animal feed. However, it appears that few direct—
`fed microbials are stable in feed for more than 3—5 days.
`(Aimutis, W. R., Feeds Management, Vol. 42, pp. 26—32
`(1991)). Moreover, some feed contains antibiotics which are
`contrary to microbials stability. Yet other feed is pelleted,
`and most Lactobacillus species, which are predominant and
`beneficial
`intestinal species. are susceptible to the high
`temperatures, compression, aeration and mixing abrasion to
`which they are exposed during the pellcting process.
`Another approach is to provide the bacteria themselves as
`a pellet or bolus. Many such bolus products are commer-
`cially available.
`More recently, bolus or pellet formulations have been
`developed which include a combination of the microorgan-
`isms and dry vitamin and trace mineral supplements. as
`nearly simultaneous administration in vivo of these compo-
`nents has been suggested as being highly beneficial to
`achieving the goals of appetite stimulation and microbial
`population reestablishrnent. Many of these bolus formula-
`tions are available commercially. It has been found, how-
`ever, that the supplements and microorganisms are incom-
`
`Page 10 of 28
`
`

`

`5,501,85'lr
`
`3
`patiblc as the vitamin and mineral levels commonly used
`and elficacious for livestock are toxic to the microorganisms
`in many formulations. The toxicity is dependent upon con-
`centration of the vitamins andlor minerals and the microor-
`ganisms used. By “toxic“ is meant that the vitamins andror
`minerals inhibit, or prevent growth or diminish viability of
`the microorganisms. By viability is meant the capability of
`life. The toxicity is demonstrated in a reduction of shelf life
`of a microorganism. As the time period in which the
`microbials are in contact with the toxic substance increases,
`the concentration of the mierobials (often expressed as
`colony forming units per gram i.e., CFUlg or colony forming
`units per bolus i.e., CFUfBolus) as measured by standard
`testing procedures, decreases. This is also expressed as
`Percent Survival Rate of the microorganism observed over
`a period of tune. As the time period increases, the Percent
`Survival Rate decreases.
`
`Thus, the CFU’s decrease as time increases. The popula-
`tion of viable microorganisms can be greatly reduced within
`a week or within approximately a month. As indicated
`previously, microorganisms are also sensitive to mixing
`abrasion, aeration, compression and high temperatures, all
`of which occur during conventional hard bolus production.
`Moreover, the bolus formulations also require binding, wet-
`ting and disintegrating agents, any or all of which may
`adversely afiect the viability of the microorganisms. Such
`bolus products, therefore, have limited shelf stability or shelf
`life, in that, the population of viable microorganisms can be
`greatly reduced within about a week or about a month.
`Thus, a persistent and vexatious problem, largely unat-
`tended by the prior art, is the lack of a method for simul—
`taneously delivering incompatible substances in vivo to
`animals, when one of the substances is a viable microor-
`ganism culture.
`Various prior art methods of physical separation, e.g.,
`encoating, encapsulation and microencapsulation, of nutri-
`tional supplements are known. however, none adequame
`address the preparation and storage requirements of sensi-
`tive direct-fed microbial agents. For example, conventional
`microencapsulation subjects microorganisms to a number of
`potentially fatal packaging procedures arid requires expen-
`sive materials, complex equipment, and carefully controlled
`environmental conditions. Polymeric microeapsules also
`require specific pH ranges or enzyme activities to elfeet
`release of their contents in vivo. These requirements often
`frustrate conventional laboratory assessment techniques and
`prevent efiective nutrient release in animals whose rumen
`andt'or gastrointestinal pH of enzyme balances have been
`disrupted by microbial depopuiation.
`U.S. Pat. No. 4,695,466 to Mori shita discloses a multiple-
`encapsulation method. The Morishita process includes suc-
`cessively encapsulating oil solutions or suspensions in soft
`capsules. Although the method of Morishita has potential for
`delivery of two components in a single vehicle, the use of oil
`carriers presents insurmountable obstacles to the delivery of
`microorganisms and vitamin supplement components. It is
`unlikely that Morishita‘s soft outer capsules will be able to
`withstand common shipping, storage and administration
`conditions and also is unlikely applicable to commonly
`available microbial forms.
`
`Despite recognition of the known drawbacks of prior art
`products, the art has not adequately responded to date with
`a method for delivery in vivo of the incompatible compo—
`nents, namely, direct-fed microbials and nutrient supple~
`ments nearly simultaneously to cattle, sheep, goats, and
`ratites.
`
`ll]
`
`15
`
`20
`
`30
`
`35
`
`45
`
`50
`
`55
`
`60
`
`65
`
`4
`SUMMARY or THE MENTION
`
`The present invention responds specifically to the long-
`felt need heretofore unmet by the prior art, and especially
`with a view to overcoming the inherent inadequacies of
`combination supplements and direct—fed microbials for oral
`delivery to animals. The composition is a dietary adjunct or
`feedstull, providing the convenience and reliability of oral
`administration, while providing near simultaneous delivery
`in vivo of direct—fed microbials and incompatible sub
`stances. such as vitamins and minerals in a partitioned
`unitary structure, a double capsule. The composition is shelf
`stable, i.e., allows substantially greater viability of micro-
`bials. and does not require binding. wetting and disintegrat-
`ing agents necessary for pellet or bolus formulations. The
`composition provides accurate unit dosage, virtually simul—
`taneous in vivo delivery of the components of the double
`capsule, and rapid in vivo dissolution.
`This invention is directed to the probiotie classes of
`publicly available direct-fed microbials which are fed to
`both ruminant animals and to non-ruminant animals. Where
`the direct~fed-microbial is ruminant specific, it is understood
`that the application is to feeding ruminant animals. However
`the scope of this invention also includes non-mminant
`animals such as other livestock. Other livestock includes,
`but is not limited to, ratites, such as ostriches and emus.
`The foregoing, and other advantages of the present inven-
`tion, are realized in one aspect thereof in an oral nutritional
`composition, i.e., a dietary adjunct, useful for treating feed-
`ing disorders and improving feed efficiency in livestock,
`e.g., cattle, sheep and goats, especially ruminants, but not
`limited to ruminants. Non-ruminants include, but are not
`limited to ratites [such as, but not limited to ostriches and
`emus). For ruminant animals,
`the gastrointestinal
`tract
`includes the rumen; for non-ruminant animals,
`the gas-
`trointestinal tract is absent a ruruen. Gastrointestinal micro-
`orgainsms inhabit the gastrointestinal tract. Gastrointestinal
`microorganisms include bacteria, live cell yeasts or fungi,
`among others.
`The dietary adjunct composition comprises a double
`capsule which includes live cultures of rumen andlor gas-
`trointestinal microorganisms in a first capsule which is
`enclosed with vitamin andl'or mineral supplements in a
`second capsule. The capsules are preferably made of a
`dissolvahle material, preferably gelatin. The microorgan-
`isms and supplements may be combined with acceptable
`feed grade
`carriers. Gastrointestinal microorganisms,
`include bacteria, live cell yeasts, fungi or a combination
`thereof. By live cell yeast is meant, a yeast culture contain-
`ing live yeast cells but not containing yeast metabolites
`andlor the yeast growth media.
`In another embodiment of this invention, this invention
`provides a dietary adjunct composition comprising a double
`capsule which includes a vitamin andfor mineral supplement
`in a first capsule which is enclosed with live gastrointestinal
`microorganisms in a second capsule. The first capSule wall
`separates the live microorganisms from the vitamins auditor
`minerals. The capsules are preferably made of gelatin. The
`microorganisms and supplements may be combined with
`acceptable feed grade carriers. Gastrointestinal nficroorgan-
`isms, include bacteria, live cell yeasts, fungi or a combina—
`tion thereof. By live cell yeast is meant, a yeast culture
`containing live yeast cells but not containing yeast metabo-
`lites andr'or the yeast growth media.
`In still another aspect, this invention comprises a double
`capsule which includes a gastrointestinal nucroorganism
`separated by a capsule wall from a feed ingredient which
`
`Page 11 of 28
`
`Page 11 of 28
`
`

`

`5,501,857
`
`5
`when stored in contact with the microorganism for a period
`of time will cause the microorganism to diminish its full
`growth potential.
`In still another embodiment, this invention provides a
`dietary adjunct composition comprising a double capsule
`which includes an inner capsule and an outer capsule. The
`outer capsule is spaced apart from and encloses the inner
`capsule. The inner capsule includes a dissolvable shell and
`a first substance therein. The outer capsule includes a
`dissolvable shell and a second substance therein. The shells
`are preferably made of gelatin. One of the substances is
`viable gastrointestinal microorganisms and the other sub-
`stance is a nutritional supplement. The nutritional supple-
`ment has the property of diminishing the shelf life of the
`microorganisms. That is, direct contact between the micro-
`organisms and the nutritional supplement for an extended
`period of time will cause the number of colony forming units
`expressed per unit quantity, i.e., CFUlg or CFUt'bolus, of the
`gastrointestinal microorganisms to decrease.
`In another aspect, the invention is a method of simulta-
`neously delivering incompatible compounds to animals in
`vivo. Such delivery is achieved by feeding an animal a
`double capsule containing a first substance in a first capsule,
`which is enclosed with a second substance, in a second
`larger capsule. One of the two substances is a viable sub-
`stance. The other substance is such that the viable substance
`is rendered nonviable when both substances are stored and
`administered simultaneously in a bolus or in a single capsule
`formulation. By “incompatible" is meant that one of the nvo
`substances prevents or inhibits the growth audlor effects the
`viability of the other substance. By viable is meant capabil-
`ity of life. The substance can come out of a dormant
`condition, such as a freeze dried state to a active vegetative
`state. The viable substance is not completely in a spore state.
`The viable substance may be in a form that has both spore
`forming and non spore forming components. As is known in
`the art, only certain of the direct-fed niicrobials have a spore
`component. In this instance, CFU include typically spore
`and nouspore forms.
`In another embodiment, this invention provides a method
`for preparing shelf-stable compositions of incompatible sub-
`stances, which includes the use of multiple capsules of
`variable composition. Such method is accomplished manu-
`ally or by machine.
`Other advantages and a fuller appreciation of the specific
`adaptations, compositional variations, and physical and
`chemical attributes of the present invention will be gained
`upon an examination of the following detailed description of
`the invention, taken in conjunction with the accompanying
`drawings and appended claims.
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`The present invention will hereinafter he described in
`conjunction with the appended drawings, wherein like des—
`ignations refer to like elements tluonghout and in which:
`FIG. 1 shows an enlarged sectional view of the capsule-
`in-a-capsule structure in accordance with the present inven-
`tion with the microorganisms within the inner capsule;
`FIGS. 2a—2f illustrate a method by which each capsule-
`in-a-capsule structure of FIG. 1 is assembled;
`FIG. 3 compares the efficacy of double capsules in
`accordance with the present invention and hard boluses in
`simultaneously delivering live microorganisms and incom-
`patible nutrient supplements;
`
`6
`
`FIG. 4 shows an enlarged sectional view of the capsule-
`in-a—capsule structure in accordance with the present inven-
`tion, with the microorganisms outside of the inner capsule
`and with the vitamins andfor minerals admixture in the inner
`capsule; and
`FIGS. 50-53“ illustrates a method by which each capsule-
`in«a~capsule structure of FIG. 4 is assembled.
`
`ll]
`
`15
`
`7.0
`
`30
`
`35
`
`45
`
`50
`
`55
`
`65
`
`DETAILED DESCRIPTION
`
`invention relates broadly to nutritional
`The present
`supplements and dietary adjuncts for animals, such as cattle,
`sheep, goats, and ratites and specifically to compositions and
`nutrient delivery systems which permit delivery of direct-fed
`microbials with incompatible substances. However,
`the
`composition of the present invention is most particularly
`adapted for use in oral supplementation formulations which
`combine nutrients, such as vitamins andr'or minerals, and
`viable gastrointestinal microorganisms,
`such as
`fungi,
`yeasts, or bacteria. Gastrointestinal microorganisms include
`intestinal microorganisms, andfor rumen microorganisms
`depending upon the animal. The gastrointestinal microor-
`ganisms include but are not limited to those dwelling in the
`stomach, large and small intestines. Accordingly, the present
`invention will now be described in detail with respect to
`such fields of endeavor; however, those skilled in the art will
`appreciate that such description of the invention is meant to
`be exemplary only and should not be viewed as limitative of
`the full scope thereof.
`The present invention provides a nutritional composition
`useful for ameliorating drug-induced, stress-related, and
`other feeding disorders in food—producing animals. The
`composition is partiCularly useful as arumlnant feedstufi for
`improving feed efficiency and promoting growth for cattle,
`sheep and goals, but may also be used in non-ruminant food
`producing animals such as ratitcs. Ratitae is a classification
`of birds and includes birds, such as ostriches, rheas, cas~
`sowaries. emus, elipbantbirds, moas, kiwis. Raising cents
`and ostricbes is popular for production of meat, hides,
`feathers and eggs. For ruminants, the composition avoids the
`milk and slaughter withdrawal periods required after drug
`treatments and enhances the general nutritional status of the
`animal. Additionally, the composition is shelf-stable and
`provides a general packaging system for incompatible mate-
`rials, and is particularly useful for direct-fed nucrohial
`agents or probiotics. These attributes are achieved through a
`particular composition meeting a special combination of
`physical parameters.
`As used herein, the term “incompatible" is meant to refer
`to substances which deleteriously react with one another
`when combined in desired levels or concentrations. The
`microbial is a substance which has a capacity of viability or
`is viable. The incompatible substance renders the microbial
`non viable when the probiotic and the incompatible sub-
`stance are stored and administered simultaneously in abolus
`or in a single capsule formulation.
`In one embodiment, the invention provides a nutritional
`composition whose components are incompatible, and
`which incompatible components are physically separated
`from each other until they reach their in vivo situs. The
`composition includes two components. One of the compo-
`nents is cultures of viable microorganisms, e.g., bacteria or
`fungi or live cell yeasts, or combinations thereof. By live cell
`yeasts is meant. a yeast culture containing live yeast cells but
`not containing yeast metabolites andlor the yeast growth
`media. The other of the components is nutritional supple-
`
`Page 12 of 28
`
`Page 12 of 28
`
`

`

`7
`
`5,501,857
`
`meats, e.g.. vitamins andror minerals. Each component
`necessary to make and use the present invention is commer—
`cially available or can be synthesized using known meth-
`odologies. The two components are separated from one
`another. One of the components is enclosed in the inner
`capsule. The outer capsule contains the inner capsule and the
`other component. In a preferred embodiment, the microbial
`cultures are enclosed in a first capsule which is then enclosed
`with the vitamin andlor mineral supplements in a second
`such capsule, i.e., a “capsule-in—a—capsule” structure. How-
`ever the invention also comprehends the reversal of the
`components, i.e., the vitamins andfor mineral supplements
`are enclosed in a first capsule which is then enclosed with
`the microorganisms in a second capsule. The microorgan-
`isms of the one component serve the valuable function of
`repopulating the rumen andlor intestines,
`thus enabling
`digestion to resume, producing digestive enzymes, and
`correcting acid imbalances which result from rumen or
`intestinal microbial microorganism depopulation.
`The vitamins andfor minerals of the other component
`increase the nutritional status of animals laboring under
`conditions of malnutrition caused by feeding disorders.
`Further, once dispersed throughout the rumen andfor intes-
`tines,
`these vitamins andlor minerals support
`the rapid
`growth of the microorganisms of the first component. Oral
`administration of these vitamins andlor minerals contempo-
`raneously with the administration of microorganisms is
`preferable to separate administration. Separate administra-
`tion increases the risk that microorganisms will not encoun-
`ter dispersed vitamins and minerals in the rumen andlor in
`the intestine and thus fail
`to exhibit
`their full growth
`potential. Also separate adminisuation increases the end
`user cost for materials and labor.
`
`In one embodiment. it has been found that the bacterial
`survival rate with the capsule-in—a—capsule structure of the
`present invention after up to six months storage, i.e., a
`shelf—life of six months after preparation, is nearly 500 times
`that of an admixture of the bacteria and nutrient supple-
`ments. Art admixture of bacterial and nutrient supplements
`is typically a single capsule or a bolus formulation.
`FIG.
`1 illustrates a capsule-in-a-capsnle structure in
`accordance with the present invention and is generally
`designated as 20. Capsule—in—a—capsule 20 includes an inner
`capsule 22 and an outer capsule 24. The inner capsule 22 is
`within the outer capsule 24. Inner capsule 22 contains viable
`microorganisms 26 and outer capsule 24 contains vitamins
`andl'or minerals generally designated as 28. Inner capsule 22
`includes a top member 30 and a bottom member 32 which
`is bigger than top member 30. Top member 30 and bottom
`member 32 are locked together after filling by a locking
`mechanism 33 which includes a groove 34 proximate the top
`35 of bottom portion 32 and a complementary ridge 36
`substantially about the mid-portion 3'? of top portion 3|),
`forming a circumferentially nested ridge and groove. Simi—
`larly, outer capsule 24 has a top member 38 and a bottom
`member 40 in which top member 38 is locked to bottom
`member 40 with a groove 42 and a ridge 44. Alternatively
`the content of the inner and outer capsules may be reversed
`as is shown in FIG. 4 and wherein the capsule—in—a~capsule
`vehicle 20' is depicted with microorganisms 26' contained
`Within the outer capsule and with the vitamin andlor mineral
`admixture 28' contained in the inner capsule. FIG. 4 illus—
`trates a capsule-in-a-capsule structure in accordance with the
`present invention and is generally designated as 20'. Cap-
`sule-in-a—capsule 20' includes an inner capsule 22' and an
`outer capsule 24'. The inner capsule 22' is within the outer
`capsule 24'. Inner capsule 22' contains vitamins andfor
`
`10
`
`15
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`65
`
`minerals generally designated as 28' and outer capsule 24‘
`contains viable microorganisms 26'.
`Inner capsule 22'
`includes a top member 30' and a bottom member 32' which
`is bigger than top member 30'. Top member 30' and bottom
`member 32‘ are locked together after filling by a locking
`mechanism 33' which includes a groove 34' proximate the
`top 35' of bottom portion 32' and a complementary ridge 36‘
`substantially about the mid~portion 37' of top portion 30'.
`forming a circumferentially nested ridge and groove. Simi-
`larly, outer capsule 24‘ has a top member 38‘ and a bottom
`member 40' in which top member 38' is locked to bottom
`member 40' with a groove 42' and a ridge 44'.
`The capsules, in either FIG. 1 or FIG. 4. are preferably
`made of gelatin, however other materials which dissolve in
`the animal‘s gastrointestinal system, as are known in the art,
`may also be used and are encompassed by the invention.
`Capsule shells are, however. easily reformulated to meet a
`myriad of size, transportation, storage, and administration
`requirements, e.g., excessive heat or cold, vibration, humid-
`ity, compression or impact, aeration, or ultraviolet light. The
`shell of the inner capsule forms a wall, separating the
`contents contained within the inner capsule from the sub-
`stance extemal to the inner capsule, but contained within the
`outer capsule.
`In snucntre 20, the microorganisms 26 of the first com-
`ponent, i.e., of inner capsule 22, include one or more of the
`indigenous gastrointestinal bacteria selected from [acroba-
`cilltts acidophilas, Lacrobact'llus lacrir, Lacrobnct’llns casei,
`Streptococcus fascittm, and Pediococcus cerevirt'ae andt'or
`microorganisms including the live cell yeast Saccharomyces
`cerevisiae. fungus Aspergillus oryzae, andr'or bacteria Bifi-
`dobacterium and Propionibacterium. All of these microbes
`are publicly available from commercial sources such as
`Far-Mot Biochem, Milwaukee, Wis. Chr. Hansen's Labora-
`tory, Inc, Milwaukee, Wis. Red Star® Yeast Products.
`Milwaukee, Wis. and Agtech Products, Inc., Waukesha, Wis.
`By live cell yeast culture is meant, a yeast culture containing
`live yeast cells but not containing yeast metabolites andl‘or
`the yeast growth media. The microorganisms can be pro-
`cessed in accordance with conventional methods of bacte—
`nology to produce direct~fed microbial agents suitable for
`encapsulation in gelatin-shelled capsules and administration
`to cattle, sheep and goats, and ratites. The in vitro viability
`of the microorganisms of the inner capsule is determined by
`counting the colony-forming units per gram (CFUI'g) of the
`culnire administered, according to standard feed industry
`protocols such as those developed by the American Feed
`Ingredients Association (AFIA) or the National Feed Ingre-
`dients Association (NFIA). At time of preparation,
`the
`microbial count in the inner capsule in accordance with the
`present invention depends upon the microorganism used and
`is suitably about 20X109 CFUlg for Iactobnct'llas acidophi—
`Eur, [acrobacillus tom's, [acrobact'lltts carei, Streptococcus
`fascium, and Pediccoccus cerevisiae; about 10x109 CFUl'g
`for live cell yeast Saccharomyces cerevisiae; about 1x107
`CFUIg for Aspen'gillus oryzae; about 20x109 CFUl’g for
`Bifidobacterium; and about 2x1011 CFUIg for Propionibac-
`terium. As is known in the art, the invention comprehends
`the use of the standard formulation overages for determining
`the amount of microbial culture present. The standard over-
`age depends on the culture used and ranges typically from 0
`to 50%. For example for the lactic acid producing bacteria
`an average of 50% is typical, for yeasts 50%, for Bifido-
`bacterium 50% for Propionibacterium 50%, and for Aspen-
`gt'llus oryzae about 0%.
`The microorganisms can be employed in admixtures with
`conventional excipients, e.g., acceptable feed grade carriers
`
`Page 13 of 28
`
`Page 13 of 28
`
`

`

`5,501,857
`
`9
`suitable for enteral [e.g. oral) administration which do not
`deleteriously react with the microorganisms. By the term
`“deleteriously react“ it is meant that the feed grade carrier
`does not inhibit, or prevent growth or diminish the viability
`of the microorganisms. Suitable feed grade carriers include,
`but are not limited to, calcium carbonate, nonhygroscopic
`whey. rice hulls, and sucrose.
`The microbial preparations can also be mixed with aux-
`iliary agents, e.g., whole dried milk, dextrose, enzymes,
`plasma proteins or amino acids to promote the growth and
`nutritional status of the animal and the microbials in vivo.
`
`The vitamins and minerals of the second component, i.e.,
`outer capsule. are selected from one or more vitamins,
`namely, A, Big, C, D, E, and K, niacin, thiamine. choline,
`biotin, folic acid, riboflavin, pantothenic acid, andl‘or one or
`more minerals, namely, cobalt, copper, iron, manganese,
`selenium and zinc.
`
`The vitamins andfor minerals of the outer capsule 28 can
`be processed in accordance with conventional methods of
`pharmacy to produce agents suitable for encapsulation in
`gelatin-shelled capsules and administration to cattle, sheep,
`goats, and ratites. For example, the vitamins and minerals
`can be administered in alternative sulfate, oxide, chelated, or
`other chemical forms to promote efficient dissolution and
`absorption in vivo.
`The vitamins andt'or minerals can also be employed in
`admixtures with conventional excipients, e.g., acceptable
`feed grade c

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket